The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate invoices.
CMS asked for the input in Medicare program guidance issued Feb. 9. The document describes pros and cons of requiring pharmacies either (a) to use the “20” claims submission clarification code at time of adjudication or dispensing or (b) requiring pharmacies to submit an “N1” claims transaction retrospectively to identify 340B-acquired drugs.
The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate invoices.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.